Advertisement

The E23K Variant of Kir6.2 Associates With Impaired Post-OGTT Serum Insulin Response and Increased Risk of Type 2 Diabetes

  1. Eva-Maria D. Nielsen1,
  2. Lars Hansen12,
  3. Bendix Carstensen1,
  4. Søren M. Echwald1,
  5. Thomas Drivsholm3,
  6. Charlotte Glümer1,
  7. Birger Thorsteinsson4,
  8. Knut Borch-Johnsen1,
  9. Torben Hansen1 and
  10. Oluf Pedersen15
  1. 1Steno Diabetes Center and Hagedorn Research Institute, Gentofte, Copenhagen, Denmark
  2. 2Clinical Genetics, Novo Nordisk, Bagsvaerd, Denmark
  3. 3Centre for Preventive Medicine, Glostrup University Hospital, Glostrup, Denmark
  4. 4Department of Internal Medicine F, Hilleroed Hospital, Hilleroed, Denmark
  5. 5Faculty of Health Science, University of Aarhus, Aarhus, Denmark

    Abstract

    The E23K polymorphism of the pancreatic β-cell ATP-sensitive K+ (KATP) channel subunit Kir6.2 (KCNJ11) is associated with type 2 diabetes in whites, and a recent in vitro study of the E23K variant suggests that the association to diabetes might be explained by a slight inhibition of serum insulin release. In a study comprising 519 unrelated glucose-tolerant subjects, we addressed the question as to whether the E23K variant was related to reduced serum insulin release during an oral glucose tolerance test (OGTT). Furthermore, the polymorphism was examined in a case-control study comprising 803 type 2 diabetic patients and 862 glucose-tolerant control subjects. The E23K variant was associated with significant reductions in the insulinogenic index (P = 0.022) and serum insulin levels under the response curve during an OGTT (0–120 min) (P = 0.014) as well as with an increase in BMI (P = 0.013). In the present study, the association of the E23K polymorphism with type 2 diabetes was not significant (P = 0.26). However, the K23K genotype significantly associated with type 2 diabetes in a meta-analysis of white case and control subjects (n = 2,824, odds ratio [OR] 1.49, P = 0.00022). In conclusion, the widespread E23K polymorphism may have a diabetogenic effect by impairing glucose-induced insulin release and increasing BMI.

    Footnotes

    • Address correspondence and reprint requests to Lars Hansen, MD, Clinical Genetics, Novo Nordisk, Krogshoejvej 53A, DK-2880 Bagsvaerd, Denmark. E-mail: larh{at}novonordisk.com.

      Received for publication 20 September 2002 and accepted in revised form 14 November 2002.

      AUC, area under the curve; IGT, impaired glucose tolerance; KATP, ATP-sensitive K+; OGTT, oral glucose tolerance test; OHA, oral hypoglycemic agents; OR, odds ratio; PHHI, persistent hyperinsulinemic hypoglycemia of infancy; SUR, sulfonylurea receptor; UKPDS, U.K. Prospective Diabetes Study.

    | Table of Contents
    Advertisement